Примери за използване на Marketing authorisation valid на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
The European Commission granted a marketing authorisation valid throughout the European Union for Elaprase to Shire Human Genetic Therapies AB on 8 January 2007.
Emtricitabine/Tenofovir disoproxil Krka received a marketing authorisation valid throughout the EU on 9 December 2016.
The European Commission granted a marketing authorisation valid throughout the European Union for ProteqFlu on 6 March 2003.
The European Commission granted a marketing authorisation valid throughout the EU for ZULVAC 8 Ovis on 15 January 2010.
The European Commission granted a marketing authorisation valid throughout the European Union,
The European Commission granted a marketing authorisation valid throughout the European Union, for Eryseng on 4 July 2014.
The European Commission granted a marketing authorisation valid throughout the European Union, for RESPIPORC FLU3 to IDT Biologika GmbH on 14/01/2010.
The European Commission granted a marketing authorisation valid throughout the European Union for Zulvac 1+8 Bovis on 08/03/2012.
The European Commission granted a marketing authorisation valid throughout the European Union, for Suvaxyn PCV on 24 July 2009.
The European Commission granted a marketing authorisation valid throughout the European Union for OPATANOL to Alcon Laboratories(UK)
The European Commission granted a marketing authorisation valid throughout the European Union for PegIntron to SP Europe on 25 May 2000.
The European Commission granted a marketing authorisation valid throughout the European Union,
The European Commission granted a marketing authorisation valid throughout the European Union for Meloxidyl to Ceva Santé Animal on 15 January 2007.
Intelence received a marketing authorisation valid throughout the EU on 28 August 2008.
Rapamune received a marketing authorisation valid throughout the EU on 14 March 2001.
Torisel received a marketing authorisation valid throughout the EU on 19 November 2007.
Zelboraf received a marketing authorisation valid throughout the EU on 17 February 2012.
Zebinix received a marketing authorisation valid throughout the EU on 21 April 2009.
Zydelig received a marketing authorisation valid throughout the EU on 18 September 2014.
Somavert received a marketing authorisation valid throughout the EU on 13 November 2002.